MCID: GNR004
MIFTS: 56

Generalized Anxiety Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

MalaCards integrated aliases for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 74 36 54 15 62 17 71 32
Anxiety Generalized 54

Classifications:



External Ids:

Disease Ontology 12 DOID:14320
KEGG 36 H01662
ICD9CM 34 300.02
NCIt 49 C92622
SNOMED-CT 67 21897009
ICD10 32 F41.1
UMLS 71 C0270549

Summaries for Generalized Anxiety Disorder

PubMed Health : 62 About generalized anxiety disorder: Everyone feels frightened or very scared every once in a while. In dangerous situations, for instance on the highway, fear can help to protect you. It puts the body in a state of readiness so that it can react to threats quickly. Worries and anxiety about the future, your job or family might also help to guard against danger. For example, by keeping you from making rash decisions that could lead to difficult situations. But if these sorts of fears become overwhelming, they can be very distressing. Some people end up constantly worrying about practically everything. If fears and anxiety overshadow everything else and don’t go away, the person may have developed generalized anxiety disorder (GAD). People with generalized anxiety disorder usually realize that their fears are exaggerated, but they aren’t able to control them. Although it’s difficult to get out of this state, there are treatments that can help.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to depression and neurotic disorder. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Valproic acid and Eszopiclone have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

KEGG : 36 Generalized anxiety disorder is a persistent and common mental disorder. This disorder is twice as common in women than it is in men. The symptoms include generalised and persistent excessive anxiety and a combination of various psychological and somatic complaints, such as threat, restlessness, irritability, sleep disturbance, tension, palpitations, dry mouth, and sweating. The symptoms overlap greatly with those of other mental disorders and we could regard the disorder as part of a spectrum of mood and related disorders rather than an independent disorder. Generalized anxiety disorder has a relapsing course, and intervention rarely results in complete resolution of symptoms. But in the short term and medium term, effective treatments include psychological therapies, such as cognitive behavioural therapy, and pharmacological treatments, mainly selective serotonin reuptake inhibitors (SSRIs).

Wikipedia : 74 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 depression 32.7 SLC6A4 MAOA HTR2A HTR1A CRHR1 BDNF
2 neurotic disorder 32.6 SLC6A4 MAOA HTR2A HTR1A BDNF
3 social phobia 31.1 SLC6A4 MAOA HTR3A HTR1A DRD2 COMT
4 dysthymic disorder 31.1 SLC6A4 MAOA HTR2A HTR1A BDNF
5 somatization disorder 31.1 SLC6A4 HTR2A HTR1A
6 withdrawal disorder 30.9 TSPO DRD2 CRHR1
7 avoidant personality disorder 30.9 TPH1 SLC6A4 SLC6A3 MAOA DRD2
8 agoraphobia 30.8 SLC6A4 SLC6A2 RGS2 MAOA HTR2A HTR1A
9 phobia, specific 30.7 SLC6A4 MAOA HTR1A COMT
10 acute stress disorder 30.7 SLC6A4 NR3C1 CRP CRHR1 BDNF
11 constipation 30.7 SLC6A4 SLC6A2 NPY HTR3A BDNF
12 sexual disorder 30.7 SLC6A4 HTR3A HTR2A HTR1A DRD2 CYP2D6
13 obsessive-compulsive personality disorder 30.6 SLC6A4 HTR2A
14 postpartum depression 30.6 SLC6A4 MAOA HTR1A COMT BDNF
15 hypochondriasis 30.6 SLC6A4 HTR3A HTR2A HTR1A BDNF
16 adjustment disorder 30.4 TSPO SLC6A4 NPY HTR2A BDNF
17 alexithymia 30.4 SLC6A4 HTR1A DRD2 CRP COMT
18 alcohol use disorder 30.3 SLC6A4 SLC6A3 HTR3A HTR2A HTR1A DRD2
19 phobic disorder 30.3 SLC6A4 MAOA HTR2A HTR1A CRHR1 COMT
20 antisocial personality disorder 30.2 SLC6A4 SLC6A3 MAOA HTR2A DRD2 COMT
21 bruxism 30.2 SLC6A4 HTR2A HTR1A DRD2
22 irritable bowel syndrome 30.2 TPH1 SLC6A4 HTR3A HTR2A HTR1A CRHR1
23 movement disease 30.1 SLC6A3 DRD2 CYP2D6
24 tic disorder 30.1 SLC6A4 SLC6A3 MAOA HTR2A DRD2 COMT
25 bipolar i disorder 30.1 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
26 eating disorder 30.1 SLC6A4 SLC6A3 NPY HTR2A DRD2 COMT
27 neuroleptic malignant syndrome 29.9 HTR3A HTR2A HTR1A DRD2 CYP2D6
28 serotonin syndrome 29.9 SLC6A4 MAOA HTR3A HTR2A HTR1A CYP2D6
29 oppositional defiant disorder 29.9 SLC6A4 SLC6A3 SLC6A2 MAOA DRD2 COMT
30 melancholia 29.8 SLC6A4 MAOA HTR2A HTR1A CRP BDNF
31 anorexia nervosa 29.7 SLC6A4 SLC6A2 NPY MAOA HTR2A HTR1A
32 anxiety 29.7 TSPO TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2
33 personality disorder 29.7 TPH1 SLC6A4 SLC6A3 NR3C1 MAOA HTR3A
34 fibromyalgia 29.7 TSPO SLC6A4 NPY HTR3A HTR2A DRD2
35 post-traumatic stress disorder 29.6 SLC6A4 NR3C1 NPY MAOA HTR2A DRD2
36 substance abuse 29.6 SLC6A4 SLC6A3 NPY MAOA HTR2A HTR1A
37 sleep disorder 29.6 SLC6A4 SLC6A3 HTR2A HTR1A DRD2 CRP
38 mental depression 29.6 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 MAOA
39 obsessive-compulsive disorder 29.6 TPH1 SLC6A4 SLC6A3 NPY NPSR1 MAOA
40 substance dependence 29.5 TPH1 SLC6A4 SLC6A3 MAOA DRD2 CYP2D6
41 panic disorder 29.5 TSPO TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2
42 dementia 29.5 TSPO SLC6A3 MAOA HTR2A HTR1A DRD2
43 myocardial infarction 29.4 SLC6A4 NPY HTR3A HTR2A CRP COMT
44 bulimia nervosa 29.4 SLC6A4 NPY MAOA HTR3A HTR2A DRD2
45 mood disorder 29.4 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 NPY
46 chronic fatigue syndrome 29.4 SLC6A4 NR3C1 NPY MAOA HTR3A HTR2A
47 tobacco addiction 29.4 TPH1 SLC6A4 SLC6A3 MAOA HTR2A DRD2
48 psychotic disorder 29.4 TPH1 SLC6A4 SLC6A3 MAOA HTR3A HTR2A
49 asthma 29.3 SLC6A4 NR3C1 NPY NPSR1 CRHR1 COMT
50 migraine with or without aura 1 29.0 TPH1 SLC6A4 SLC6A3 NPY MAOA HTR3A

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 18)


Acute Cystitis Anxiety
Bronchitis Dependent Personality Disorder
Dysthymic Disorder Esophagitis
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Irritable Bowel Syndrome Major Depressive Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Osteoporosis Personality Disorder
Schizophreniform Disorder Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:



Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 BDNF COMT CRHR1 CYP1A2 DRD2 HTR1A
2 homeostasis/metabolism MP:0005376 10.3 BDNF COMT CRHR1 CRP CYP1A2 DRD2
3 cardiovascular system MP:0005385 10.25 COMT CRHR1 CRP CYP1A2 DRD2 HTR1A
4 endocrine/exocrine gland MP:0005379 10.14 BDNF COMT CRHR1 CYP1A2 DRD2 HTR2A
5 nervous system MP:0003631 10.07 BDNF COMT CRHR1 DRD2 HTR1A HTR3A
6 muscle MP:0005369 9.92 DRD2 HTR2A HTR3A NR3C1 RGS2 SLC6A3
7 no phenotypic analysis MP:0003012 9.7 BDNF CRHR1 CYP1A2 DRD2 HTR1A NR3C1
8 normal MP:0002873 9.61 BDNF CRHR1 DRD2 NPY NR3C1 RGS2
9 respiratory system MP:0005388 9.23 BDNF COMT CRHR1 CYP1A2 DRD2 NPSR1

Drugs & Therapeutics for Generalized Anxiety Disorder

PubMed Health treatment related to Generalized Anxiety Disorder: 62

There are different ways to gradually get a handle on an anxiety disorder . It is unrealistic to expect a quick and simple “cure,” but you can find better ways to deal with stress and anxiety. Medication may also relieve some of the symptoms. There are different kinds of treatment approaches: Psychological treatments : These include approaches like cognitive behavioral therapy . This therapy can help you to learn how to control and then change your thoughts and fears. Relaxation techniques such as autogenic training and progressive muscle relaxation can help you to relax and handle stress better. These techniques are often part of psychological treatment . Medication: The most commonly used medications for anxiety disorders are antidepressants. Some people also use herbal sedatives such as valerian. Self-help: Self-help groups offer you the opportunity to share your thoughts, feelings and experiences with others who have the same condition. Some people also find it helpful to learn more about the disorder – be it from books, information leaflets or on the Internet. It is hard to get a handle on severe anxiety , but many people succeed over time. A therapist can help to reveal the underlying patterns of the worries and anxiety. With their guidance, it is possible to learn how to control harmful thoughts and behavior patterns so that they no longer dominate your life. It can take a lot of patience to find your way back to a life with less anxiety, but a noticeable improvement can often already be achieved after a few weeks.

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
3
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
4
Lorazepam Approved Phase 4 846-49-1 3958
5
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
6
Zolpidem Approved Phase 4 82626-48-0 5732
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Chamomile Approved, Experimental, Investigational Phase 4
9
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
10
Ethanol Approved Phase 4 64-17-5 702
11
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
12
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
13
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
14
Citalopram Approved Phase 4 59729-33-8 2771
15
Norepinephrine Approved Phase 4 51-41-2 439260
16
Sodium citrate Approved, Investigational Phase 4 68-04-2
17
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
18
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
19
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
20
Ziprasidone Approved Phase 4 146939-27-7 60854
21
Methadone Approved Phase 4 76-99-3 4095
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
24
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
25
Black cohosh Experimental Phase 4
26 Tandospirone Investigational Phase 4 87760-53-0
27 Antimanic Agents Phase 4
28 Serotonin 5-HT1 Receptor Agonists Phase 4
29 Antiemetics Phase 4
30 Gastrointestinal Agents Phase 4
31 GABA-A Receptor Agonists Phase 4
32 GABA Agonists Phase 4
33 Dopamine D2 Receptor Antagonists Phase 4
34 Serotonin 5-HT2 Receptor Antagonists Phase 4
35 Dopamine agonists Phase 4
36 Sympathomimetics Phase 4
37 Vasoconstrictor Agents Phase 4
38 Anti-Ulcer Agents Phase 4
39 Antacids Phase 4
40 Proton Pump Inhibitors Phase 4
41 Butylscopolammonium Bromide Phase 4
42 Mydriatics Phase 4
43 Bromides Phase 4
44 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
45 Citrate Phase 4
46 Chelating Agents Phase 4
47 Anticoagulants Phase 4
48 Antiparkinson Agents Phase 4
49 Muscarinic Antagonists Phase 4
50 Autonomic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 428)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
2 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
3 The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder. Completed NCT00235508 Phase 4 Eszopiclone (Lunesta)
4 Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial Completed NCT02219880 Phase 4
5 Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder Completed NCT01118780 Phase 4 Duloxetine;Placebo
6 Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
7 Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia Completed NCT00902564 Phase 4 Escitalopram
8 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects Completed NCT01033851 Phase 4
9 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
10 Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro) Completed NCT00296790 Phase 4 zolpidem tartrate
11 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
12 Chamomile Therapy for Generalized Anxiety Disorder Completed NCT00645983 Phase 4
13 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4 Continued Paroxetine CR;Quetiapine;Placebo
14 A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
15 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly Completed NCT00701675 Phase 4 sertraline 50 mg daily;sertraline 100 mg daily;Placebo 50 or 100 mg
16 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
17 Short-term Versus Long-term Treatment in Generalized Anxiety Disorder Completed NCT00183274 Phase 4 Venlafaxine XR;Placebo
18 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
19 Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder Completed NCT00892463 Phase 4 Quetiapine (Seroquel) XR
20 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
21 Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation Completed NCT00219349 Phase 4 escitalopram
22 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC) Completed NCT01201967 Phase 4
23 Pharmacotherapy of Late-Life Generalized Anxiety Disorder Completed NCT00105586 Phase 4 Escitalopram
24 Randomized, Double-blind, Placebo-controlled Study of a Benzodiazepine vs Placebo on Functional Magnetic Resonance Imaging (fMRI) of the Brain, and on Behavioral/Clinical Measures in Patients With Generalized Anxiety Disorder Completed NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
25 Black Cohosh Therapy for Menopause-Related Anxiety Completed NCT00120458 Phase 4
26 Long-Term Lorazepam Use and Acute Toxicity in the Aged Completed NCT00044642 Phase 4 Lorazepam
27 A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
28 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
29 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
30 The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
31 A Double-blind, Controlled, Randomized Study Comparing Escitalopram Combined With Scopolamine or Escitalopram in Patients With Major Depressive Disorder Completed NCT03131050 Phase 4 Scopolamine;Escitalopram;Saline
32 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
33 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
34 A 14 Week Open-Label Study to Evaluate the Tolerability of Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction in Generalized Anxiety Disorder Patients Completed NCT00174850 Phase 4 Gaitril
35 Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia Completed NCT01349413 Phase 4 Esomeprazole 20mg
36 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial Recruiting NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
37 Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities Recruiting NCT01975480 Phase 4 Desvenlafaxine
38 Impact of Duloxetine on Male Fertility Recruiting NCT03038867 Phase 4 Duloxetine
39 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
40 Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders Active, not recruiting NCT02579928 Phase 4 Ketamine;Midazolam
41 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Enrolling by invitation NCT03271151 Phase 4 Cymbalta
42 Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder Terminated NCT00374543 Phase 4 Ziprasidone;Placebo
43 A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
44 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
45 An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin Terminated NCT01128712 Phase 4 Pregabalin;Pregabalin
46 An Open-label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines in Treatment-refractory Patients With Unipolar Depression or Generalized Anxiety Disorder and Chronic Benzodiazepine Use Terminated NCT01244711 Phase 4 quetiapine
47 Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder Withdrawn NCT01546896 Phase 4 buspirone+alprazolam;alprazolam
48 The Effect of Saffron (Crocus Satious L.) in the Treatment of Mild to Moderate Generalized Anxiety Disorder: a Double Blind Randomized Controlled Trial Unknown status NCT02800733 Phase 2, Phase 3
49 A Double-blind, Randomized, Controlled, Phase III Study of an Herbal Medicine Association for Generalized Anxiety Disorder Unknown status NCT01178632 Phase 3 Passiflora;Valeriana officinalis
50 A Study of the Effectiveness and Tolerability of Duloxetine (Cymbalta) in the Treatment of PTSD. Unknown status NCT00583193 Phase 3 Duloxetine hydrochloride

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

40
Brain, Heart, Testes, Breast, Amygdala, Cortex, Eye

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 5887)
# Title Authors PMID Year
1
Duloxetine in the treatment of generalized anxiety disorder. 54 61
19337457 2008
2
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. 54 61
18840371 2008
3
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. 54 61
18344738 2008
4
Azapirones for generalized anxiety disorder. 54 61
16856115 2006
5
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. 54 61
16722631 2006
6
Early response and 8-week treatment outcome in GAD. 54 61
16845651 2006
7
Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. 54 61
15722951 2005
8
SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. 54 61
15538601 2004
9
Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. 54 61
15450911 2004
10
Occupancy of agonist drugs at the 5-HT1A receptor. 54 61
14985704 2004
11
Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. 54 61
12555227 2003
12
Serotonin, 5-hydroxyindoleacetic acid and serotonin transporter in blood peripheral lymphocytes of patients with generalized anxiety disorder. 54 61
12188031 2002
13
Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. 54 61
11444684 2001
14
Inverse agonist binding of peripheral benzodiazepine receptors in anxiety disorder. 54 61
11697575 2001
15
Decreased platelet peripheral-type benzodiazepine receptors in adolescent inpatients with repeated suicide attempts. 54 61
10459397 1999
16
Benzodiazepine-induced chemotaxis is impaired in monocytes from patients with generalized anxiety disorder. 54 61
10101731 1999
17
Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. 54 61
10356651 1999
18
Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. 54 61
9606532 1998
19
Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. 54 61
9399689 1997
20
[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?]. 54 61
9064274 1996
21
Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder. 54 61
8866701 1996
22
A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. 54 61
8748432 1995
23
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder. 54 61
7714223 1995
24
The role of serotonin in depression and anxiety. 54 61
7622823 1995
25
Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder. 54 61
9160582 1994
26
Peripheral-type benzodiazepine receptors in anxiety disorders. 54 61
1686517 1991
27
Prevalence and Predictors of Distress, Anxiety, Depression, and Quality of Life in Bereaved Family Caregivers of Patients With Advanced Cancer. 61
31596115 2020
28
Association between Generalized Anxiety Disorder and Premenstrual Dysphoric Disorder in a Diagnostic Interviewing Study. 61
32033286 2020
29
A Retrospective Study to Identify Novel Factors Associated with Post-stroke Anxiety. 61
31859033 2020
30
Psychological disturbances in patients with pigmentary disorders: a cross-sectional study. 61
31566833 2020
31
Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series. 61
31724120 2020
32
Barriers to mental health treatment among individuals with social anxiety disorder and generalized anxiety disorder. 61
30070552 2020
33
Multimodal Categorical and Dimensional Approaches to Understanding Threat Conditioning and Its Extinction in Individuals With Anxiety Disorders. 61
32022832 2020
34
Psychometric properties of worry and anxiety measures in a sample of african american and caucasian older adults. 61
30810345 2020
35
Impact of Wartime Stress Exposures and Mental Health on Later-Life Functioning and Disability in Vietnam-Era Women Veterans: Findings From the Health of Vietnam-Era Women's Study. 61
31714370 2020
36
Association of antepartum depression, generalized anxiety, and posttraumatic stress disorder with infant birth weight and gestational age at delivery. 61
31733923 2020
37
Anxiety and Fear-Related Disorders in the ICD-11: Results from a Global Case-controlled Field Study. 61
32018071 2020
38
Post-traumatic stress disorder, psychiatric comorbidities and associated factors among refugees in Nakivale camp in southwestern Uganda. 61
32033558 2020
39
Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer. 61
31652379 2020
40
Fast time perception is associated with high levels of anxiety in cancer patients prior to starting chemotherapy. 61
32023559 2020
41
Augmenting the unified protocol for transdiagnostic treatment of emotional disorders with transcranial direct current stimulation in individuals with generalized anxiety disorder and comorbid depression: A randomized controlled trial. 61
31740106 2020
42
Gender-specific predictors of generalized anxiety disorder symptoms in older adults: Results of a large population-based study. 61
31668601 2020
43
Predicting likelihood of psychological disorders in PlayerUnknown's Battlegrounds (PUBG) players from Asian countries using supervised machine learning. 61
31704370 2020
44
When to Raise Our White Flag-A Discussion of Scope of Practice in a Resource Scarce World. 61
31917736 2020
45
Functional somatic illnesses in patients with functional bowel disorders. A cross-sectional cohort study in western Saudi Arabia. 61
32020157 2020
46
Investigating behavior inhibition in obsessive-compulsive disorder: Evidence from eye movements. 61
32027033 2020
47
Measurement invariance of assessments of depression (PHQ-9) and anxiety (GAD-7) across sex, strata and linguistic backgrounds in a European-wide sample of patients after Traumatic Brain Injury. 61
31732280 2020
48
Search trends preceding increases in suicide: A cross-correlation study of monthly Google search volume and suicide rate using transfer function models. 61
31733460 2020
49
Noise annoyance predicts symptoms of depression, anxiety and sleep disturbance 5 years later. Findings from the Gutenberg Health Study. 61
32034913 2020
50
Feasibility of implementing mobile technology-delivered mental health treatment in routine adult sickle cell disease care. 61
30508141 2020

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 TSPO NR3C1 NPY NPSR1 HTR2A HTR1A
2 12.17 NPY HTR1A DRD2 BDNF
3 11.97 TPH1 SLC6A4 NR3C1 MAOA HTR3A HTR2A
4
Show member pathways
11.87 SLC6A3 MAOA DRD2 BDNF
5 11.86 TPH1 SLC6A4 MAOA HTR3A HTR2A HTR1A
6
Show member pathways
11.81 HTR2A HTR1A DRD2
7
Show member pathways
11.77 SLC6A4 SLC6A2 CYP2D6 CYP1A2 COMT
8
Show member pathways
11.7 TPH1 MAOA CYP1A2
9
Show member pathways
11.65 TPH1 MAOA CYP1A2
10
Show member pathways
11.51 CYP2D6 CYP1A2 COMT
11
Show member pathways
11.34 SLC6A4 SLC6A3 SLC6A2 MAOA
12 11.25 MAOA CYP2D6 CYP1A2
13
Show member pathways
11.04 SLC6A4 SLC6A3 MAOA COMT
14
Show member pathways
11 TPH1 MAOA COMT
15 10.88 TPH1 SLC6A4 MAOA HTR3A HTR2A HTR1A
16
Show member pathways
10.84 HTR3A CYP2D6 CYP1A2
17
Show member pathways
10.76 MAOA COMT
18 10.72 MAOA COMT
19 10.56 MAOA CYP2D6 CYP1A2
20
Show member pathways
10.53 SLC6A4 SLC6A3 SLC6A2 MAOA HTR1A DRD2

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.33 TSPO SLC6A4 SLC6A3 SLC6A2 RGS2 NPSR1
2 integral component of membrane GO:0016021 10.22 TSPO SLC6A4 SLC6A3 SLC6A2 NPSR1 MAOA
3 integral component of plasma membrane GO:0005887 9.91 SLC6A4 SLC6A3 SLC6A2 NPSR1 HTR3A HTR2A
4 neuron projection GO:0043005 9.8 TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2 HTR3A
5 dendrite GO:0030425 9.77 HTR2A HTR1A DRD2 COMT BDNF
6 axon GO:0030424 9.63 SLC6A3 HTR3A HTR2A DRD2 COMT BDNF
7 dopaminergic synapse GO:0098691 9.43 SLC6A3 DRD2
8 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 SLC6A3 HTR3A HTR2A DRD2
9 integral component of postsynaptic membrane GO:0099055 9.02 SLC6A4 SLC6A3 HTR3A HTR2A DRD2

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 NR3C1 NPSR1 HTR3A HTR2A HTR1A DRD2
2 G protein-coupled receptor signaling pathway GO:0007186 10.14 RGS2 NPY NPSR1 HTR2A HTR1A DRD2
3 chemical synaptic transmission GO:0007268 9.83 SLC6A2 NPY HTR3A HTR2A HTR1A
4 memory GO:0007613 9.8 SLC6A4 HTR2A BDNF
5 response to ethanol GO:0045471 9.76 SLC6A3 RGS2 HTR3A DRD2
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.75 NPY HTR2A HTR1A
7 neurotransmitter transport GO:0006836 9.7 SLC6A4 SLC6A3 SLC6A2
8 response to cocaine GO:0042220 9.69 SLC6A3 HTR3A DRD2
9 vasoconstriction GO:0042310 9.66 SLC6A4 HTR1A
10 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD2 CRHR1
11 oxidative demethylation GO:0070989 9.65 CYP2D6 CYP1A2
12 prepulse inhibition GO:0060134 9.65 SLC6A3 DRD2
13 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.64 HTR2A DRD2
14 dopamine metabolic process GO:0042417 9.64 DRD2 COMT
15 neurotransmitter biosynthetic process GO:0042136 9.63 SLC6A4 SLC6A3
16 behavior GO:0007610 9.62 HTR2A HTR1A
17 neurotransmitter catabolic process GO:0042135 9.62 MAOA COMT
18 regulation of dopamine metabolic process GO:0042053 9.61 SLC6A3 HTR1A
19 catecholamine metabolic process GO:0006584 9.61 MAOA COMT
20 adenohypophysis development GO:0021984 9.6 SLC6A3 DRD2
21 neurotransmitter reuptake GO:0098810 9.58 SLC6A4 SLC6A2
22 heterocycle metabolic process GO:0046483 9.57 CYP2D6 CYP1A2
23 drug catabolic process GO:0042737 9.56 CYP2D6 CYP1A2
24 monoterpenoid metabolic process GO:0016098 9.55 CYP2D6 CYP1A2
25 dopamine uptake involved in synaptic transmission GO:0051583 9.54 SLC6A3 SLC6A2
26 estrogen metabolic process GO:0008210 9.54 CYP2D6 CYP1A2 COMT
27 response to pain GO:0048265 9.5 TSPO SLC6A2 COMT
28 norepinephrine uptake GO:0051620 9.49 SLC6A3 SLC6A2
29 norepinephrine transport GO:0015874 9.48 SLC6A3 SLC6A2
30 dopamine catabolic process GO:0042420 9.43 SLC6A3 MAOA COMT
31 alkaloid metabolic process GO:0009820 9.4 CYP2D6 CYP1A2
32 monoamine transport GO:0015844 9.33 SLC6A4 SLC6A3 SLC6A2
33 response to drug GO:0042493 9.23 TSPO SLC6A4 SLC6A3 SLC6A2 HTR2A DRD2
34 serotonin receptor signaling pathway GO:0007210 9.13 HTR3A HTR2A HTR1A

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.46 SLC6A3 HTR2A DRD2 CYP2D6
2 neurotransmitter:sodium symporter activity GO:0005328 9.43 SLC6A4 SLC6A3 SLC6A2
3 dopamine binding GO:0035240 9.4 SLC6A3 DRD2
4 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A2
5 norepinephrine:sodium symporter activity GO:0005334 9.32 SLC6A3 SLC6A2
6 monoamine transmembrane transporter activity GO:0008504 9.13 SLC6A4 SLC6A3 SLC6A2
7 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Generalized Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....